You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAliskiren
Accession NumberDB09026  (DB01258)
TypeBiotech
GroupsApproved, Investigational
DescriptionNot Available
Protein structureNo structure small
Protein chemical formulaNot Available
Protein average weightNot Available
Sequences
SynonymsNot Available
SaltsNot Available
Brand namesNot Available
Brand mixturesNot Available
CategoriesNot Available
CAS numberNot Available
Taxonomy
KingdomNot Available
SuperclassNot Available
ClassNot Available
SubclassNot Available
Direct parentNot Available
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
Statesolid
Experimental PropertiesNot Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ResourceLink
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AlfuzosinMonitor therapy due to enhanced hypotensive effect of aliskiren.
AmifostineAmifostine hypotensive effect can be exacerbated with administration of antihypertensives. If amifostine is administered, no antihypertensives should be administered within 24 hours. If the antihypertensives can't be withheld, amifostine should not be administered.
AtorvastatinTherapy modification should be considered because atorvastatin increases aliskiren serum concentration.
BrimonidineMonitor therapy because of enhanced hypotensive effect.
CanagliflozinMonitor therapy because canagliflozin may enhance aliskiren antihypertensive and hyperkalemic effects.
CyclosporineAvoid combination because cyclosporine increases aliskiren serum concentration.
DiazoxideMonitor therapy due to enhanced hypotensive effect of aliskiren.
DuloxetineMonitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
FurosemideMonitor therapy due to potential decreased serum concentration of furosemide.
HeparinMonitor therapy due to enhanced hyperkalemic effect of aliskiren.
ItraconazoleAvoid combination due to increased serum concentration of aliskiren.
KetoconazoleMonitor therapy due to increased serum concentration of aliskiren.
MethylphenidateMonitor therapy due to reduced antihypertensive effect of aliskiren.
ObinutuzumabObinutuzumab antihypertensive effect may be enhanced. Administration of antihypertensives should be withheld 12 hours before infusion of obinutuzumab and 1 hour after the end of infusion.
PentoxifyllineMonitor therapy due to enhanced antihypertensive effects of aliskiren.
RituximabConsider therapy modification due to enhanced hypotensive effect of rituximab.
VerapamilMonitor therapy due to increased concentration of aliskiren.
YohimbineMonitor therapy due to decreased antihypertensive effects of aliskiren.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on October 13, 2014 16:29 / Updated on October 13, 2014 16:29